Applied Clinical Trials is the thought leader in pharmaceutical drug development operations and clinical trial design, management, and monitoring.

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

In the Phase III ENVISION trial, Zusduri achieved a 24-month duration of response rate of 72.2% among patients with a ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, shares key ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

In the Phase III TRIUMpH program, tegoprazan met primary endpoints and outperformed lansoprazole in maintaining healing of ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...

The US Department of Health and Human Services has terminated 22 mRNA vaccine research contracts under BARDA, signaling a ...